What Happened?
Burlington, -based Generex Promoted Mark Fletcher as Executive Vice President, General Counsel and Secretary
Date of management change: November 15, 2018
Burlington, -based Generex Promoted Mark Fletcher as Executive Vice President, General Counsel and Secretary
Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator. Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with the global biopharmaceutical companies by providing a financing solution to them as sponsors of clinical trials, which are conducted by patient care providers (PCPs) such as hospitals, medical research institutes, centers, and clinics.
Mark Fletcher is Executive Vice President, General Counsel and Secretary at Generex. Previously, Mark held various senior legal leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Shaw Amy, Swift Marie, Sobecki Judi, Rouleau Mark, Yelton Jonathan, Marson Jonas, Goodwin William, Gibbs Kimberly, Jones Kristine, Cademartori Joe, Vasic Gordana
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.